Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant symptom relief trends.
Tag: Investor Relations
Appen Limited (ASX:APX) Reports 16% Revenue Growth and Outlines 2025 Strategy
Appen Limited (ASX:APX) reports 16% revenue growth in 2024 and outlines strategic plans for sustainable growth in 2025.
Simble Solutions Limited (ASX:SIS) Announces 2024 Operational Highlights and Strategic Partnerships
Simble Solutions Limited (ASX:SIS) reports significant 2024 operational achievements and strategic partnerships, driving growth and expansion.
Tempest Minerals Limited (ASX:TEM) Reports Excellent Metallurgical Results for Remorse Deposit
Tempest Minerals Limited (ASX:TEM) reports excellent initial metallurgical results for the Remorse Deposit at Yalgoo Project.
HITIQ Limited (ASX:HIQ) Announces Entitlement Issue to Raise up to $2.92 Million
HITIQ Limited (ASX:HIQ) launches a non-renounceable entitlement issue aiming to raise up to $2.92 million to expand manufacturing and USA operations.
Chimeric Therapeutics (ASX:CHM) Reports Positive ADVENT-AML Trial Results
Chimeric Therapeutics (ASX:CHM) reports that two of three patients achieved complete response in its ADVENT-AML Phase 1B clinical trial.
Tamboran Resources Corporation (ASX:TBN) Announces 3Q FY25 Results
Tamboran Resources Corporation (ASX:TBN) announces 3Q FY25 results, highlighting successful well completions and financial milestones.
Bass Oil Limited (ASX:BAS) Announces Rights Issue and Strategic Acquisitions
Bass Oil Limited (ASX:BAS) announces a rights issue and strategic acquisitions to accelerate growth and unlock long-term value for investors.
Epsilon Healthcare Limited (ASX:EPN) Announces Issue of $1M Loan Notes
Epsilon Healthcare Limited (ASX:EPN) issues loan notes to raise $1 million for operational expansion and diversification.
WCM Global Growth Limited (ASX:WQG) Declares Increased Dividend
WCM Global Growth Limited (ASX:WQG) declares a fully franked dividend of 1.89c per share for Q3 FY2025 and outlines a progressive dividend policy.